Literature DB >> 21767228

Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study.

Jordan E Lake1, David Wohl, Rebecca Scherzer, Carl Grunfeld, Phyllis C Tien, Stephen Sidney, Judith S Currier.   

Abstract

HIV-infected individuals are at increased risk for cardiovascular disease (CVD) and lipodystrophy, but the relationship between regional adipose tissue (AT) depots and CVD risk is not well described. We determined regional AT volumes and CVD risk in an analysis of 586 HIV-infected and 280 control FRAM study subjects using whole-body magnetic resonance imaging (MRI) and the Framingham Risk Score (FRS). Median FRS and FRS >10% were higher in HIV than control men (4.7% vs. 3.7%, p=0.0002; 16% vs. 4%, p<0.0001). HIV and control women had similarly low FRS (1.1% vs. 1.2%, p=0.91). In controls, total AT and all regional AT depots showed strong positive correlations with FRS (p<0.001) in men and weaker positive correlations in women. Greater visceral AT (VAT) and lower leg subcutaneous AT (SAT) volumes were associated with elevated FRS in HIV subjects with a trend for upper trunk SAT. Controls in the lowest quartile of leg SAT had the lowest FRS (1.5%), whereas HIV with similarly low leg SAT had the highest FRS (4.0%, p<0.001 vs. controls). Increased VAT is associated with CVD risk, but the risk is higher in HIV-infected individuals relative to controls at every level of VAT. Peripheral lipoatrophy (as measured by leg SAT) is associated with striking increased CVD risk in HIV-infected patients even after controlling for VAT, whereas low leg SAT is associated with low CVD risk in controls.

Entities:  

Mesh:

Year:  2011        PMID: 21767228      PMCID: PMC3249238          DOI: 10.1080/09540121.2010.543885

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  34 in total

1.  Fat distribution in men with HIV infection.

Authors:  Peter Bacchetti; Barbara Gripshover; Carl Grunfeld; Steven Heymsfield; Heather McCreath; Dennis Osmond; Michael Saag; Rebecca Scherzer; Michael Shlipak; Phyllis Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2005-10-01       Impact factor: 3.731

2.  Fat distribution in women with HIV infection.

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

3.  Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

Authors:  T Saint-Marc; M Partisani; I Poizot-Martin; O Rouviere; F Bruno; R Avellaneda; J M Lang; J A Gastaut; J L Touraine
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

4.  Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.

Authors:  J H Stein; M A Klein; J L Bellehumeur; P E McBride; D A Wiebe; J D Otvos; J M Sosman
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

5.  Increased cardiovascular disease risk indices in HIV-infected women.

Authors:  Sara E Dolan; Colleen Hadigan; Kathleen M Killilea; Meghan P Sullivan; Linda Hemphill; Robert S Lees; David Schoenfeld; Steven Grinspoon
Journal:  J Acquir Immune Defic Syndr       Date:  2005-05-01       Impact factor: 3.731

6.  Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial.

Authors:  Kathleen Mulligan; Robert A Parker; Lauren Komarow; Steven K Grinspoon; Pablo Tebas; Gregory K Robbins; Ronenn Roubenoff; Michael P Dubé
Journal:  J Acquir Immune Defic Syndr       Date:  2006-04-15       Impact factor: 3.731

7.  Ten-year predicted coronary heart disease risk in HIV-infected men and women.

Authors:  Robert C Kaplan; Lawrence A Kingsley; A Richey Sharrett; Xiuhong Li; Jason Lazar; Phyllis C Tien; Wendy J Mack; Mardge H Cohen; Lisa Jacobson; Stephen J Gange
Journal:  Clin Infect Dis       Date:  2007-09-12       Impact factor: 9.079

8.  Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.

Authors:  Virginia A Triant; Hang Lee; Colleen Hadigan; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2007-04-24       Impact factor: 5.958

9.  The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics.

Authors:  Phyllis C Tien; Constance Benson; Andrew R Zolopa; Stephen Sidney; Dennis Osmond; Carl Grunfeld
Journal:  Am J Epidemiol       Date:  2006-03-08       Impact factor: 4.897

10.  The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat.

Authors:  Delma J Nieves; Miriam Cnop; Barbara Retzlaff; Carolyn E Walden; John D Brunzell; Robert H Knopp; Steven E Kahn
Journal:  Diabetes       Date:  2003-01       Impact factor: 9.461

View more
  35 in total

1.  Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone.

Authors:  Netanya S Utay; Douglas W Kitch; Eunice Yeh; Carl J Fichtenbaum; Michael M Lederman; Jacob D Estes; Claire Deleage; Clara Magyar; Scott D Nelson; Karen L Klingman; Barbara Bastow; Amneris E Luque; Grace A McComsey; Daniel C Douek; Judith S Currier; Jordan E Lake
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

2.  Adiponectin and interleukin-6, but not adipose tissue, are associated with worse neurocognitive function in HIV-infected men.

Authors:  Jordan E Lake; Quynh T Vo; Lisa P Jacobson; Ned Sacktor; Eric N Miller; Wendy S Post; James T Becker; Frank J Palella; Ann Ragin; Eileen Martin; Cynthia A Munro; Todd T Brown
Journal:  Antivir Ther       Date:  2015-03-26

3.  The association of adiposity with kidney function decline among HIV-infected adults: findings from the Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) study.

Authors:  A Malkina; R Scherzer; M G Shlipak; P Bacchetti; P C Tien; C Grunfeld; L Kosmiski; C A Peralta
Journal:  HIV Med       Date:  2014-09-23       Impact factor: 3.180

4.  Physical fitness in children infected with the human immunodeficiency virus: associations with highly active antiretroviral therapy.

Authors:  Gabriel Somarriba; Gabriela Lopez-Mitnik; David A Ludwig; Daniela Neri; Natasha Schaefer; Steven E Lipshultz; Gwendolyn B Scott; Tracie L Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-31       Impact factor: 2.205

5.  Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus.

Authors:  Paula Debroy; Jordan E Lake; Carlee Moser; Maxine Olefsky; Kristine M Erlandson; Ann Scherzinger; James H Stein; Judith S Currier; Todd T Brown; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

Review 6.  Aging metabolism: intervention strategies.

Authors:  Esteban Martinez
Journal:  Virulence       Date:  2017-03-13       Impact factor: 5.882

7.  Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

Authors:  Priya Bhagwat; Ighovwerha Ofotokun; Grace A McComsey; Todd T Brown; Carlee Moser; Catherine A Sugar; Judith S Currier
Journal:  Antivir Ther       Date:  2017-03-01

8.  Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy.

Authors:  Chris T Longenecker; Ying Jiang; Chun-Ho Yun; Sara Debanne; Nicholas T Funderburg; Michael M Lederman; Norma Storer; Danielle E Labbato; Hiram G Bezerra; Grace A McComsey
Journal:  Int J Cardiol       Date:  2013-07-22       Impact factor: 4.164

9.  Increased FDG uptake in association with reduced extremity fat in HIV patients.

Authors:  Martin Torriani; Markella V Zanni; Kathleen Fitch; Eleni Stavrou; Miriam A Bredella; Ruth Lim; Aaron M Cypess; Steven Grinspoon
Journal:  Antivir Ther       Date:  2012-10-05

Review 10.  Human immunodeficiency virus and acquired immunodeficiency syndrome: recent developments and their implications for pediatric surgeons.

Authors:  A Cooper
Journal:  Semin Pediatr Surg       Date:  1995-11       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.